President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
He argues the administration’s theory that tariffs will force price cuts is flawed, especially for patented, brand-name drugs where there is no competition and demand is inelastic.
